Sugi Predict

Sugi Predict / Compounds / SCHEMBL30327420

SCHEMBL30327420

SCHEMBL30327420

CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ EPHA2 P29317 2/20 0.69
▸ NMUR2 Q9GZQ4 5/20 0.58
▸ NMUR1 Q9HB89 5/20 0.58
▸ C5AR1 P21730 1/20 0.57
▸ OPRM1 P35372 5/20 0.56
▸ OPRD1 P41143 1/20 0.56
▸ TFPI P10646 4/20 0.55
▸ KDM1A O60341 1/20 0.54
▸ OPRK1 P41145 4/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30327403 0.91 EPHA2 (0.68) EPHA2NMUR2NMUR1C5AR1OPRM1
SCHEMBL30335928 0.91 EPHA2 (0.68) EPHA2NMUR2NMUR1C5AR1OPRM1
SCHEMBL32670411 0.90 EPHA2 (0.68) EPHA2NMUR2NMUR1C5AR1OPRM1
SCHEMBL31307234 0.89 EPHA2 (0.61) EPHA2NMUR2NMUR1C5AR1KDM1A
SCHEMBL30558096 0.86 SLC6A2 (0.60) EPHA2NMUR2NMUR1C5AR1OPRM1
SCHEMBL31307255 0.85 EPHA2 (0.58) EPHA2NMUR2NMUR1C5AR1TFPI
SCHEMBL31415963 0.84 EPHA2 (0.62) EPHA2NMUR2NMUR1C5AR1OPRM1
SCHEMBL30312779 0.84 NTSR1 (0.72) —
SCHEMBL30440169 0.84 EPHA2 (0.60) EPHA2NMUR2NMUR1OPRM1OPRD1
SCHEMBL31307252 0.83 EPHA2 (0.63) EPHA2C5AR1OPRM1OPRD1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034197-A1 Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases BETAVIVE LTD. (IL) 2026-02-05 — — US disclosed
US-12447198-B2 Peptides and fragments for treating diabetes and associated metabolic diseases BETAVIVE LTD. (IL) 2025-10-21 — — US disclosed
US-20230120635-A1 Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases BETAVIVE LTD. (IL) 2023-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230120635-A1 Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases IAPP, IGFBP2, IGFBP1 EPHA2 1995/4885NMUR2 966/4885NMUR1 1160/4885
US-12447198-B2 Peptides and fragments for treating diabetes and associated metabolic diseases IAPP, IGFBP2, IGFBP1 EPHA2 1995/4885NMUR2 966/4885NMUR1 1160/4885
US-20260034197-A1 Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases IAPP, GLP1R, IGF1R EPHA2 1718/4885NMUR2 754/4885NMUR1 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback